Rigel Pharmaceuticals, Inc.
RIGL
$42.58
$1.794.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 321.91M | 364.23M | 367.02M | 113.30M | 97.82M |
| Total Depreciation and Amortization | 2.65M | 2.41M | 2.42M | 2.42M | 2.43M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -222.36M | -271.55M | -274.27M | -29.17M | -29.51M |
| Change in Net Operating Assets | -22.81M | -15.82M | -19.51M | -18.37M | -4.91M |
| Cash from Operations | 79.39M | 79.27M | 75.66M | 68.18M | 65.83M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | -38.00K | -36.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 72.00K | 98.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -49.06M | -89.79M | -92.37M | -77.95M | -41.00M |
| Cash from Investing | -49.06M | -89.79M | -92.37M | -77.92M | -40.94M |
| Total Debt Issued | 40.00M | -- | -- | -- | -- |
| Total Debt Repaid | -62.75M | -15.00M | -7.50M | -- | -- |
| Issuance of Common Stock | 9.38M | 7.94M | 8.10M | 6.64M | 2.53M |
| Repurchase of Common Stock | -4.25M | -3.74M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.30M | -- | -- | 0.00 | -10.00M |
| Cash from Financing | -22.92M | -10.80M | 601.00K | 6.64M | -7.48M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.41M | -21.32M | -16.11M | -3.10M | 17.41M |